Overview
- Researchers presented the DECAF results at the American Heart Association Scientific Sessions and published the full trial in JAMA on November 9, 2025.
- The trial enrolled 200 older adults scheduled for cardioversion and randomized them to at least one daily caffeinated coffee or to complete caffeine abstinence for six months.
- Recurrent atrial fibrillation or atrial flutter occurred in 47% of the coffee group versus 64% of the abstinence group, with events verified by ECGs and clinician review.
- Participants typically consumed about one cup per day and were habitual or recent coffee drinkers, so findings may not apply to non-drinkers or heavy caffeine users, and energy drinks were not studied.
- Key limitations include self-reported intake, some caffeine consumption in the abstinence arm, and no detailed tracking of exercise or diet, and proposed protective mechanisms remain speculative.